Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The...

In a study of data from the Pulmonary Hypertension Association Registry in the US, researchers looked at who was more likely to skip...

A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an...

The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial...

Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new...

Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size...

The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...

Great news for the Pulmonary Hypertension (PH) community! Through the Canadian Drug Agency's (CDA) funding initiative for rare diseases,...

As most PH clinics are in large cities, PH patients living in rural or remote areas and who must travel long distances to their clinic...

We are pleased to announce that sotatercept, a new drug for patients diagnosed with pulmonary arterial hypertension (PAH), is now listed...

Tune in to the latest episode of the PHaware podcast, where Dr. Jason Weatherald, a pulmonologist at the University of Alberta, delves...

The US Food and Drug Administration (FDA) has granted approval for the medication sotatercept, a significant milestone in the treatment...

In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance...

PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read...

About Advances in Pulmonary Hypertension magazine: Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension...

Clinicians at 17 US pulmonary hypertension centres were interviewed about their understanding of social determinants of health in...

This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...

In February, the panCanadian Pharmaceutical Alliance entered into formal pricing negotiations with the manufacturer of Opsyvni...

This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...

In other diseases, palliative care is associated with better quality of life, symptom management, illness understanding, and reduced...